MANCHESTER KEITH S
SEC CIK 1244828 · EDGAR
BoughtSold
Most active insiders at ROIV, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | MANCHESTER KEITH S | Dir | — | $154.47M |
| 2 | Gold Daniel Allen | Dir | — | $147.38M |
| 3 | QVT Financial LP | Dir by Deputization | — | $147.38M |
| 4 | Sukhatme Mayukh | Pres, CIO, Dir | — | $109.13M |
| 5 | Ramaswamy Vivek | 10% | — | $105.88M |
| 6 | Venker Eric | Pres, Immunovant CEO | — | $89.77M |
| 7 | Torti Frank | Pres, Vant COB | — | $82.04M |
| 8 | Gline Matthew | CEO, Dir | — | $46.17M |
| 9 | Pulik Richard | CFO | — | $9.12M |
| 10 | Fitzgerald Meghan | Dir | — | $3.27M |
Transactions 18
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-18 21:00 | 2026-09-16 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | A - Grant | $0.00 | +5,054 | 1.75M | +0.3% | $0 |
| MI | 2026-06-30 20:38 | 2026-06-26+ | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | S - Sale | $34.32 | -1.44M | 13.69M | -10% | -$49.35M |
| 2026-06-30 20:38 | 2026-06-30 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | S - Sale | $35.45 | -200.0K | 1.75M | -10% | -$7.09M | |
| MI | 2026-02-13 | 2026-02-11+ | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | S - Sale | $26.64 | -1.23M | 15.13M | -7% | -$32.66M |
| MI | 2025-12-18 | 2025-12-16+ | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | S - Sale | $23.05 | -1.69M | 16.54M | -9% | -$39.07M |
| MI | 2025-11-21 | 2025-11-19 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | S - Sale | $20.23 | -1.30M | 18.05M | -7% | -$26.30M |
| D | 2025-09-12 | 2025-09-10 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | A - Grant | $0.00 | +14.5K | 1.95M | +0.8% | $0 |
| MI | 2025-06-27 | 2025-06-25 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | J - Other | $0.00 | -17.39M | 1.59M | -92% | $0 |
| M | 2024-09-26 | 2024-09-24+ | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | S - Sale | $11.67 | -503.0K | 1.28M | -28% | -$5.87M |
| D | 2024-09-12 | 2024-09-10 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | A - Grant | $0.00 | +16.4K | 1.78M | +0.9% | $0 |
| D | 2024-08-16 | 2024-08-14 | ABUS | Arbutus Biopharma Corp | MANCHESTER KEITH S | Dir | S - Sale+OE | $3.69 | -8,846 | 46.1K | -16% | -$32.6K |
| D | 2024-08-16 | 2024-08-14 | ABUS | Arbutus Biopharma Corp | MANCHESTER KEITH S | Dir | M - OptEx | $0.56 | +54.9K | 54.9K | New | +$30.8K |
| MI | 2024-03-07 | 2024-03-07 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | J - Other | $0.00 | -30.26M | 2.76M | -92% | $0 |
| MI | 2023-10-02 | 2023-09-28 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | S - Sale | $11.55 | -6.90M | 34.43M | -17% | -$79.65M |
| D | 2023-09-14 | 2023-09-12 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | A - Grant | $0.00 | +17.8K | 70.0K | +34% | $0 |
| MI | 2022-11-14 | 2022-11-10 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | S - Sale | $4.75 | -3.92M | 37.49M | -9% | -$18.63M |
| I | 2022-11-14 | 2022-11-09 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | J - Other | — | -1.20M | 38.58M | -3% | — |
| D | 2022-09-19 | 2022-09-15 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Dir | A - Grant | $0.00 | +52.1K | 52.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations